Citation: Aiping Chen, Yue Zhong, Yunxiao Liu, Zhancheng Xie, Hanyu Wu, Wei Shi, Wenlong Huang, Renxiang Tan, Hai Qian. Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations[J]. Chinese Chemical Letters, ;2023, 34(6): 107923. doi: 10.1016/j.cclet.2022.107923 shu

Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations

Aiping Chen ^{a, 1} ,
Yue Zhong ^{b, 1} ,
Yunxiao Liu ^b ,
Zhancheng Xie ^b ,
Hanyu Wu ^b ,
Wei Shi ^b ,
Wenlong Huang ^b ,
Renxiang Tan ^{a, *,} ,
Hai Qian ^{b, c, *,}

a.
College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China
b.
Center of Drug Discovery, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
c.
Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China

^**

rxtan@nju.edu.cn

qianhai24@163.com

Received Date: 6 August 2022
Revised Date: 12 October 2022
Accepted Date: 18 October 2022
Available Online: 28 October 2022

Figures(6)

The abnormal activation of BRD4 accelerates the progression of acute myeloid leukemia (AML), developing more precise therapeutics to intervene BRD4 promise to be an excellent opportunity to avoid current limitations of chemotherapy in clinic. Herein, a range of small-molecule PROTACs with the privileged 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one scaffold were rationally designed, which harbored different carbon or ethylenedioxy chains to degrade BRD4 mediated by the E3 ubiquitin ligase CRBN. Among them, the most potential B24 exhibited remarkable BRD4 degradation and excellent anti-proliferative activities in MV4-11 cells, with values of DC₅₀ and IC₅₀ for 0.75 nmol/L and 0.4 nmol/L, respectively, which were better than the BRD4 inhibitor (+)-JQ-1. Notably, this compound could time-dependently degrade the target protein in the BRD4-, CRBN-, and proteasome-dependent manner. Besides, B24 dramatically decreased the level of proto-oncogene c-Myc, and induced cell apoptosis by arresting the cell cycle in G0/G1 phase, down-regulating Bcl-2 and up-regulating Bax to amplify apoptotic effectors. This proof-of-concept study also highlighted the feasibility of BRD4-based PROTACs as a more powerful strategy against AML.
- Acute myeloid leukemia,
- BRD4,
- PROTACs,
- Protein degradation,
- Apoptosis
1. [1]
  N.J. Short, M.E. Rytting, J.E. Cortes, Lancet 392 (2018) 593–606. doi: 10.1016/S0140-6736(18)31041-9
2. [2]
  Y. Zhong, R.Z. Qiu, S.L. Sun, et al., J. Med. Chem. 63 (2020) 12403–12428. doi: 10.1021/acs.jmedchem.0c00696
3. [3]
  R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, CA Cancer J. Clin. 72 (2022) 7–33. doi: 10.3322/caac.21708
4. [4]
  Y.Y. Mao, H.C. Cai, K.N. Shen, et al., Ann. Hematol. 101 (2022) 831–836. doi: 10.1007/s00277-022-04764-4
5. [5]
  S.P. He, G.Q. Dong, Y. Li, et al., Angew. Chem. Int. Ed. 59 (2020) 3028–3032. doi: 10.1002/anie.201915896
6. [6]
  C.L. Miranda Furtado, M.C. Dos Santos Luciano, R.D. Silva Santos, et al., Epigenetics 14 (2019) 1164–1176. doi: 10.1080/15592294.2019.1640546
7. [7]
  E. Kulikowski, B.D. Rakai, N.C.W. Wong, Med. Res. Rev. 41 (2021) 223–245. doi: 10.1002/med.21730
8. [8]
  L. Feng, G. Wang, Y. Chen, et al., Med. Res. Rev. 42 (2022) 710–743. doi: 10.1002/med.21859
9. [9]
  P. Filippakopoulos, J. Qi, S. Picaud, et al., Nature 468 (2010) 1067–1073. doi: 10.1038/nature09504
10. [10]
  J.C. Chen, P. Tang, Y.X. Wang, et al., J. Med. Chem. 65 (2022) 5184–5211. doi: 10.1021/acs.jmedchem.1c01835
11. [11]
  Z. Liu, P. Wang, H. Chen, et al., J. Med. Chem. 60 (2017) 4533–4558. doi: 10.1021/acs.jmedchem.6b01761
12. [12]
  Y.F. Li, J. Zhao, L.M. Gutgesell, et al., J. Med. Chem. 63 (2020) 7186–7210. doi: 10.1021/acs.jmedchem.0c00456
13. [13]
  A.V. Gavai, D. Norris, G. Delucca, et al., J. Med. Chem. 64 (2021) 14247–14265. doi: 10.1021/acs.jmedchem.1c00625
14. [14]
  P.G. Humphreys, S.J. Atkinson, P. Bamborough, et al., J. Med. Chem. 65 (2022) 2262–2287. doi: 10.1021/acs.jmedchem.1c01747
15. [15]
  X.H. Guan, N. Cheryala, R.M. Karim, et al., J. Med. Chem. 65 (2022) 10441–10458. doi: 10.1021/acs.jmedchem.2c00453
16. [16]
  F. Jiang, Q.H. Hu, Z.M. Zhang, et al., J. Med. Chem. 62 (2019) 11080–11107. doi: 10.1021/acs.jmedchem.9b01010
17. [17]
  Y. Zhong, F.L. Chi, H.Y. Wu, et al., Eur. J. Med. Chem. 231 (2022) 114142. doi: 10.1016/j.ejmech.2022.114142
18. [18]
  M. Toure, C.M. Crews, Angew. Chem. Int. Ed. 55 (2016) 1966–1973. doi: 10.1002/anie.201507978
19. [19]
  Y. Wang, X.Y. Jiang, F. Feng, W.Y. Liu, H.P. Sun, Acta Pharm. Sin. B 10 (2020) 207–238. doi: 10.3390/molecules25010207
20. [20]
  L.C. Bai, B. Zhou, C.Y. Yang, et al., Cancer Res. 77 (2017) 2476–2487.
21. [21]
  J. Lu, Y.M. Qian, M. Altieri, et al., Chem. Biol. 22 (2015) 755–763. doi: 10.1016/j.chembiol.2015.05.009
22. [22]
  K. Raina, J. Lu, Y.M. Qian, et al., Proc. Natl. Acad. Sci. U.S.A. 113 (2016) 7124–7129. doi: 10.1073/pnas.1521738113
23. [23]
  G.E. Winter, D.L. Buckley, J. Paulk, et al., Science 348 (2015) 1376–1381. doi: 10.1126/science.aab1433
24. [24]
  M. Zengerle, K.H. Chan, A. Ciulli, ACS Chem. Biol. 10 (2015) 1770–1777. doi: 10.1021/acschembio.5b00216
25. [25]
  X.Z. Bi, J.M. Li, J.H. Li, et al., Bioorg. Med. Chem. 27 (2019) 2813–2821. doi: 10.1016/j.bmc.2019.05.006
26. [26]
  Z.Y. Feng, A.P. Chen, J. Shi, et al., Bioorg. Chem. 111 (2021) 104849. doi: 10.1016/j.bioorg.2021.104849
27. [27]
  Q.F. Li, J.M. Li, Y. Cai, et al., Bioorg. Med. Chem. 28 (2020) 115601. doi: 10.1016/j.bmc.2020.115601
28. [28]
  W. Xiang, Q.W. Wang, K. Ran, et al., Bioorg. Chem. 115 (2021) 105238. doi: 10.1016/j.bioorg.2021.105238
29. [29]
  Z.Z. Li, S.H. Xiao, Y.X. Yang, et al., J. Med. Chem. 63 (2020) 3956–3975. doi: 10.1021/acs.jmedchem.9b01784
30. [30]
  K.F. McDaniel, L. Wang, T. Soltwedel, et al., J. Med. Chem. 60 (2017) 8369–8384. doi: 10.1021/acs.jmedchem.7b00746
31. [31]
  K.H. Chan, M. Zengerle, A. Testa, A. Ciulli, J. Med. Chem. 61 (2018) 504–513. doi: 10.1021/acs.jmedchem.6b01912
32. [32]
  W.G. Xiang, L.J. Zhao, X. Han, et al., J. Med. Chem. 64 (2021) 13487–13509. doi: 10.1021/acs.jmedchem.1c00900
33. [33]
  B.B. Liu, X.H. Liu, L.L. Han, et al., Proc. Natl. Acad. Sci. U.S.A. 119 (2022) e2109133119. doi: 10.1073/pnas.2109133119
34. [34]
  G. Zhang, J. Zhang, Y.T. Gao, Y.F. Li, Y.Z. Li, Expert Opin. Drug Discov. 17 (2022) 55–69. doi: 10.1080/17460441.2021.1969359
1. [1]
  Keliang Li , Guoqiang Dong , Shanchao Wu , Chunquan Sheng . Discovery of an activatable near-infrared fluorescent and theranostic PROTAC for tumor-targeted detecting and degrading of BRD4. Chinese Chemical Letters, 2025, 36(6): 110280-. doi: 10.1016/j.cclet.2024.110280
2. [2]
  Weijian Zhang , Xianyu Deng , Liying Wang , Jian Wang , Xiuting Guo , Lianggui Huang , Xinyi Wang , Jun Wu , Linjia Jiang . Poly(ferulic acid) nanocarrier enhances chemotherapy sensitivity of acute myeloid leukemia by selectively targeting inflammatory macrophages. Chinese Chemical Letters, 2024, 35(9): 109422-. doi: 10.1016/j.cclet.2023.109422
3. [3]
  Liangyu Zhang , Lei Lei , Zhuangzhuang Zhao , Guizhi Yang , Kaitao Wang , Liying Wang , Ningxin Zhang , Yanjia Ai , Xinqing Ma , Guannan Liu , Meng Zhao , Jun Wu , Dongjun Lin , Chun Chen . Enhanced venetoclax delivery using l-phenylalanine nanocarriers in acute myeloid leukemia treatment. Chinese Chemical Letters, 2025, 36(6): 110316-. doi: 10.1016/j.cclet.2024.110316
4. [4]
  Jisheng Liu , Junli Chen , Xifeng Zhang , Yin Wu , Xin Qi , Jie Wang , Xiang Gao . Red blood cell membrane-coated FLT3 inhibitor nanoparticles to enhance FLT3-ITD acute myeloid leukemia treatment. Chinese Chemical Letters, 2024, 35(9): 109779-. doi: 10.1016/j.cclet.2024.109779
5. [5]
  Yongjian Jiang , Feng Cheng , Jun Zhou , Lei Zhan , Chunmei Li , Chengzhi Huang . Regulation of cancer cell apoptosis with DNA nanocalculator. Chinese Chemical Letters, 2026, 37(1): 110071-. doi: 10.1016/j.cclet.2024.110071
6. [6]
  Yang Liu , Jing Liang , Mengzhu Zheng , Haoze Song , Lixia Chen , Hua Li . PD-L1/SHP2 dual PROTACs inhibit melanoma by enhancing T-cell killing activity. Chinese Chemical Letters, 2025, 36(6): 110317-. doi: 10.1016/j.cclet.2024.110317
7. [7]
  Mengjie Gao , Zhiqiang Cui , Yue Shen , Yikun Li , Dongxiang Zhang , Xiaoyan Gao , Yaguang Sun , Xin-Dong Jiang , Jianjun Du , Xiaohong Sun . NIR-II emissive aza-BODIPY-based nanoparticles for triggering glioblastoma apoptosis in brain. Chinese Chemical Letters, 2025, 36(5): 110098-. doi: 10.1016/j.cclet.2024.110098
8. [8]
  Honghao Sun , Huimin Zhao , Ronghui Yin , Chenxi Zhou , Ming Wu , Yueyang Deng , Zhanwei Zhou , Minjie Sun . Injectable hydrogel-based tumor vaccine with fibrotic tumor immune microenvironment remodeling to prevent breast cancer postoperative recurrence and metastases. Chinese Chemical Letters, 2025, 36(5): 110067-. doi: 10.1016/j.cclet.2024.110067
9. [9]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
10. [10]
  Shiyang Sun , Ning Yang , Yaqiu Mao , Ting Wei , Pengli Wei , Tingting Yang , Yixin Zhang , Jian Yan , Changkai Jia , Yi Li , Xu Cai , Zhiyuan Zhao , Xuesong Feng , Xiaomei Zhuang , Wenpeng Zhang , Junhai Xiao , Pengyun Li , Zhibing Zheng , Song Li . Rational design of VHL-recruiting KRAS^G12C proteolysis-targeting chimeras based on molecular dynamics simulation. Chinese Chemical Letters, 2026, 37(2): 110992-. doi: 10.1016/j.cclet.2025.110992
11. [11]
  Xue-Jiao Wang , Jun-Li Xin , Hong Xiang , Ze-Yu Zhao , Yu-Hang He , Haibo Wang , Guangyao Mei , Yi-Cheng Mao , Juan Xiong , Jin-Feng Hu . Holotrichones A and B, potent anti-leukemic lindenane-type sesquiterpene trimers with unprecedented complex carbon skeletons from a rare Chloranthus species. Chinese Chemical Letters, 2024, 35(12): 109682-. doi: 10.1016/j.cclet.2024.109682
12. [12]
  Wenyi Mei , Lijuan Xie , Xiaodong Zhang , Cunjian Shi , Fengzhi Wang , Qiqi Fu , Zhenjiang Zhao , Honglin Li , Yufang Xu , Zhuo Chen . Design, synthesis and biological evaluation of fluorescent derivatives of ursolic acid in living cells. Chinese Chemical Letters, 2024, 35(5): 108825-. doi: 10.1016/j.cclet.2023.108825
13. [13]
  Zhiyu Yu , Xiang Luo , Cheng Zhang , Xin Lu , Xiaohui Li , Pan Liao , Zhongqiu Liu , Rong Zhang , Shengtao Wang , Zhiqiang Yu , Guochao Liao . Mitochondria-targeted carrier-free nanoparticles based on dihydroartemisinin against hepatocellular carcinoma. Chinese Chemical Letters, 2024, 35(10): 109519-. doi: 10.1016/j.cclet.2024.109519
14. [14]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
15. [15]
  Zhengyi Shi , Jie Yin , Yang Xiao , Zhangrong Hou , Fei Song , Jianping Wang , Qingyi Tong , Changxing Qi , Yonghui Zhang . Unprecedented sesquiterpene-polycyclic polyprenylated acylphloroglucinol adduct against acute myeloid leukemia via inhibiting mitochondrial complex Ⅴ. Chinese Chemical Letters, 2024, 35(10): 109458-. doi: 10.1016/j.cclet.2023.109458
16. [16]
  Yifan Feng , Chengjuan Chen , Anqi Shao , Qingyang Zhang , Lan Sun , Hai-Yu Hu , Tiantai Zhang . Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs. Chinese Chemical Letters, 2025, 36(12): 110963-. doi: 10.1016/j.cclet.2025.110963
17. [17]
  Menglu Guo , Ying-Qi Song , Junfei Cheng , Guoqiang Dong , Xun Sun , Chunquan Sheng . Hydrophobic tagging-induced degradation of NAMPT in leukemia cells. Chinese Chemical Letters, 2024, 35(9): 109392-. doi: 10.1016/j.cclet.2023.109392
18. [18]
  Yeling Yuan , Lihua Du , Kejing Zeng , Yilu Zheng , Huaping Huang , Yu Shao , Wenqing Wang , Leping Yan , Jun Wu , Changhua Zhang , Hongman Xue , Haozhe He . Hyaluronic acid-modified MOF nanoparticles for encapsulating asparaginase in T-cell acute lymphoblastic leukemia treatment. Chinese Chemical Letters, 2026, 37(1): 111222-. doi: 10.1016/j.cclet.2025.111222
19. [19]
  Si Ha , Jiacheng Zhu , Hua Xiang , Guoshun Luo . Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives. Chinese Chemical Letters, 2024, 35(8): 109192-. doi: 10.1016/j.cclet.2023.109192
20. [20]
  Zhendong Liu , Sainan Liu , Bin Liu , Qi Meng , Meng Yuan , Chunzheng Yang , Yulong Bian , Ping'an Ma , Jun Lin . Fe(Ⅲ)-juglone nanoscale coordination polymers for cascade chemodynamic therapy through synergistic ferroptosis and apoptosis strategy. Chinese Chemical Letters, 2024, 35(11): 109626-. doi: 10.1016/j.cclet.2024.109626

Get Citation

PDF

XML

Metrics

PDF Downloads(7)
Abstract views(1512)
HTML views(124)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142